Stocklytics Platform
Asset logo for symbol PRME
Prime Medicine
PRME56
$1.28arrow_drop_up4.87%$0.06
Penny Stock
Asset logo for symbol PRME
PRME56

$1.28

arrow_drop_up4.87%

Analyst Forecast

Period: Next 12 Months

Analyst Ratings

Prime Medicine (PRME) Stocklytics Forecast

Prime Medicine, Inc. (PRME) is an innovative biotechnology company that is focused on revolutionizing the field of medicine through the development of advanced gene editing therapies. With their cutting-edge technology and highly experienced team of scientists, Prime Medicine is poised to make significant breakthroughs in the treatment of various genetic diseases.
When it comes to predicting the stock price of Prime Medicine, Inc. (PRME), there are several factors to consider. One approach is to use AI algorithms and machine learning techniques to analyze historical stock data and make predictions based on patterns and trends. These advanced algorithms can take into account various market indicators, company financials, industry trends, and other relevant factors to generate accurate forecasts.
add Prime Medicine to watchlist

Keep an eye on Prime Medicine

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

What is the analyst price prediction for Prime Medicine (PRME) stock?

Analysts have set a target price of $21.1 for Prime Medicine (PRME), based on forecasts from 10 analysts. The predicted price range extends from a high of $27 to a low of $10. This represents a potential increase of up to 2K% and a decrease of 678.21% from the current price of $1.28. These forecasts are as of 2022 Nov 14.
help

What are the analyst ratings for Prime Medicine (PRME) stock?

Currently, there are no analyst ratings available for Prime Medicine (PRME), possibly due to insufficient coverage or recent updates.
help

What is the AI price prediction for Prime Medicine (PRME) stock?

At present, there is no AI or machine-learning-based price prediction available for Prime Medicine (PRME) stock. The lack of a forecast could stem from various factors, such as inadequate data or the necessity for model recalibration.

Take Your Investments to a Whole New Level